Skip to main content

Please send feedback to Peter Kappus.

DERM (Deep Ensemble for Recognition of Malignancy)

Benefits

Streamlines patient pathways by classifying lesions by risk level, supports NHS 28-day Faster Diagnosis Standard, reduces waiting times, frees up specialist capacity, provides faster accurate assessments, helps manage increasing demand while maintaining high standards of care

View source URL for details

Details

Tool name
DERM (Deep Ensemble for Recognition of Malignancy)
Status
live
AI method (as recorded)
Computer Vision, Machine Learning
AI method (normalised tags)
Computer Vision Machine Learning
Usecase
Health AI
Owning team
Broadgreen Hospital's dermatology team, NHS University Hospitals of Liverpool (UHL) Group
Date added
5 August 2025
Scrape date
Source note
NICE has granted conditional approval for NHS use, recommending continued deployment for three years while further evidence is gathered. Broadgreen's dermatology team was among the UK's first to pioneer DERM at a local medical centre, integrating it into the urgent skin cancer pathway. [Source]